Drugs / autologous immunoglobulin idiotype-KLH conjugate vaccine
autologous immunoglobulin idiotype-KLH conjugate vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002787 | Mar 1996 → Dec 2002 | plasma cell myeloma | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00621036 | Oct 2007 → Dec 2008 | central nervous system neoplasm, lymphoma, lymphoproliferative syndrome, small intestine cancer | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous immunoglobulin idiotype-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621036 ↗ |
| Modality | Vaccine | “The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor.” NCT00002787 ↗ |
| Route | Subcutaneous | “multiple subcutaneous vaccinations” NCT00002787 ↗ |